This is the authors' abstract. We don't add key points for this paper.
, CD44⁺ HCT116-TR cells induced extensive lung metastasis with elevated CD44, p-SPHK1, and p-STAT3 expression, whereas CD44-deficient mice injected with TRAIL-resistant CMT-93 cells showed minimal metastatic burden and reduced pathway activation, confirming the essential role of CD44 in TRAIL-associated metastasis. TCGA colon cancer analysis further revealed CD44 overexpression in tumors and its association with poor overall survival. Collectively, these findings show that acquired TRAIL resistance promotes CD44-mediated CSC expansion and metastatic potential through SPHK1/STAT3 activation, highlighting CD44 as a key therapeutic target in CRC.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: